Theriva Biologics Inc 2025年季度报告

FORM10-Q OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 Commission File Number:001-12584 THERIVA BIOLOGICS,INC.(Exact name of registrant as specified in its charter) (301)417-4364(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required tofile such reports), and (2)has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer, “accelerated filer,”“smaller reporting company” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large Accelerated Filer☐Accelerated Filer☐Non-accelerated Filer☒Smaller Reporting Company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section13(a)of the ExchangeAct.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ As ofMay 12, 2025,the registrant had8,186,989shares of common stock, $0.001 par value per share, outstanding. THERIVA BIOLOGICS, INC. NOTEREGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27Aof the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Actof 1934, as amended (the “Exchange Act”). In particular, statements contained in this Quarterly Report on Form10-Q, including but not limited to, statements regarding the timing of our clinical trials, the development andcommercialization of our pipeline products, the sufficiency of our cash, our ability to finance our operations andbusiness initiatives and obtain funding for such activities and the timing of any such financing, our future resultsof operations and financial position, business strategy and plans prospects, or costs and objectives of managementforfuture research,development or operations,are forward-looking statements.These forward-lookingstatements relate to our future plans, objectives, expectations and intentions and may be identified by words suchas “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “targets,” “projects,” “contemplates,”“believes,” “seeks,” “goals,” “estimates,” “predicts,” “potential” and “continue” or similar words. Readers arecautioned that these forward-looking statements are based on our current beliefs, expectations and assumptionsand are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identifiedbelow, under Part II, Item 1A. “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q, and thoseidentified under Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024 filedon March 6, 2025 (the “2024 Form 10-K”). Therefore, actual results may differ materially and adversely fromthose expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise orupdate any forward-looking statements for any reason. NOTEREGARDING COMPANY REFERENCES Throughout this Quarterly Report on Form 10-Q, “Theriva Biologics,” the “Company,” “we,” “us” and “our”refer to Theriva Biologics, Inc. and our subsidiaries Theriva Biologics, S.L. (“VCN”, formerly known as VCNBiosciences, S.L.), Pipex Therapeutics, Inc. (“Pipex Therapeutics”), Effective Pharmaceuticals, Inc. (“EPI”),Solovax,Inc.(“Solovax”),CD4 Biosciences,Inc.(“CD4”),Epitope Pharmaceuticals,Inc.(“Epitope”),Healthmine, Inc. (“Healthmine”), Putney Drug Corp. (“Putney”) and Synthetic Biomics, Inc. (“SYN Biomics”). NOTEREGARDING TRADEMARKS All trademarks, trade names and service marks appearing in this Quarterly Report on Form10-Q are the propertyof their respective owners. THERIVA BIOLOGICS,INC. FORM10-QTABLE OF CONTENTS PagePARTI. FINANCIAL INFORMATION3Item1.Financial Statements (Unaudited)3Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 20243Condensed Consolidated Statements of Operations and Comprehensive Loss for the ThreeMonths ended March 31, 2025 and 20244Condensed Consolidated Sta